Physician profile
Chris B Mathis
NPI 1407826282
$2,498.49
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,282 · 2020: $73.89 · 2021: $37.28 · 2022: $27.86 · 2023: $56.62 · 2024: $20.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $532.06 | 2019 | |
| Glaxosmithkline, LLC. | $360.84 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $328.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.49 | 2019 | |
| Merck Sharp & Dohme LLC | $147.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $115.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.38 | 2019 | |
| Astellas Pharma US INC | $93.70 | 2019 | |
| Amgen INC. | $76.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $72.30 | 2019 | |
| Amarin Pharma, INC. | $62.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.19 | 2019 | |
| Daiichi Sankyo INC. | $44.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.36 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $19.89 | 2019 | |
| Allergan, INC. | $17.17 | 2019 | |
| Tactile Systems Technology INC | $13.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.